Opus Medical Therapies, founded with a mission to innovate in the field of cardiac care, focuses on developing transcatheter mitral and tricuspid valve replacement products. The company's core vision is to address the challenging mitral regurgitation market with its proprietary transseptal transcatheter mitral valve replacement (TMVR) device. This device leverages a unique anchoring platform designed to secure any intracardiac implant while allowing normal cardiac motion, effectively treating both primary and secondary mitral regurgitation.

Notable figures associated with Opus Medical Therapies include leading cardiologists and biomedical engineers who contribute to the company's innovative edge. The startup has attracted significant interest from investors in the medical device sector, recognizing its potential to revolutionize cardiac care. Key achievements include successful preclinical trials demonstrating the efficacy and safety of their TMVR device. Overall, Opus Medical Therapies is poised to make a substantial impact on the treatment of mitral regurgitation, improving patient outcomes and advancing the field of transcatheter heart valve therapy.